116 related articles for article (PubMed ID: 3839754)
1. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
Luyckx M; Cazin JL; Brunet C; Gosselin P; Demaille MC
Eur J Clin Pharmacol; 1985; 28(4):457-62. PubMed ID: 3839754
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.
Iven H; Brasch H; Engster J
Cancer Chemother Pharmacol; 1985; 15(2):115-20. PubMed ID: 4017160
[TBL] [Abstract][Full Text] [Related]
4. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.
Crom WR; Pratt CB; Green AA; Champion JE; Crom DB; Stewart CF; Evans WE
J Clin Oncol; 1984 Jun; 2(6):655-61. PubMed ID: 6539365
[TBL] [Abstract][Full Text] [Related]
5. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
[TBL] [Abstract][Full Text] [Related]
7. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
[TBL] [Abstract][Full Text] [Related]
8. Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.
Cano JP; Bruno R; Lena N; Favre R; Iliadis A; Imbert AM
Cancer Drug Deliv; 1985; 2(4):271-6. PubMed ID: 3864520
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
Piekarczyk A; Zimak J; Taljański W
Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
Goh TS; Wong KY; Lampkin B; O'Leary J; Gnarra D
Cancer Chemother Pharmacol; 1979; 3(3):177-80. PubMed ID: 316745
[TBL] [Abstract][Full Text] [Related]
14. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
15. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
16. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
17. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
18. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate.
Gadgil SD; Damle SR; Advani SH; Vaidya AB
Cancer Treat Rep; 1982 May; 66(5):1169-71. PubMed ID: 7083219
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
20. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]